Recent Updates
Recently added Catalysts
SIBN Positive Sentiment

SI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025

Key Takeaway: SI-BONE, Inc. will participate in the Goldman Sachs 46th Global Healthcare Conference on June 10, 2025. The company will host a fireside chat at 8:20 a.m. PT, which will be accessible to investors via a live webcast. SI-BONE is recognized for its innovative technologies in treating sacropelvic disorders.
Price reaction · baseline $18.49 (2025-05-28 close) · hit after-hours · clean, no other SIBN news in the window
day 0 close · peak
+2.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE is actively engaging with investors at a major healthcare conference.
  • The company has a strong history of innovation in sacropelvic disorder treatments.
  • The webcast will provide valuable insights into SI-BONE's advancements and future plans.

Full Press Release Details

SANTA CLARA, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Goldman Sachs 46thGlobal Healthcare Conference in Miami Beach, FL. Management will be hosting a fireside chat on Tuesday, June 10, 2025, at 8:20 a.m. Pacific Time/11:20 a.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link:Glodman Sachs 46thHealthcare Conference. Live audio of the webcast will be available on the “Investors” section of the company’s website at:www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009 with the iFuse Implant System®, SI-BONE has supported over 4,500 physicians in performing a total of over 120,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies with over 160 peer reviewed publications including two randomized controlled trials. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation and pelvic trauma.
For additional information on the company or the products, including risks and benefits, please visitwww.si-bone.com.
SI-BONE,Sacropelvic Solutions,iFuse Implant System®, iFuse Bedrock Granite,andiFuse TORQ, are registered trademarks, andiFuse 3D, iFuse TORQ TNT, andiFuse INTRAare trademarks of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved.

Frequently Asked Questions

When will SI-BONE present at the conference?

SI-BONE will present on June 10, 2025, at 8:20 a.m. PT.

How can investors listen to the conference call?

Investors can register for the call and access the live audio on SI-BONE's website.

What is SI-BONE known for?

SI-BONE specializes in technologies for treating sacropelvic disorders.

How many procedures has SI-BONE supported?

SI-BONE has supported over 120,000 procedures since 2009.

Last updated: May 28, 2025